outcomes of cll patients following treatment with a covalent btk and bcl2 inhibitor
Published 2 years ago • 102 plays • Length 1:19Download video MP4
Download video MP3
Similar videos
-
2:26
outcomes of ven-based regimens in cll/sll following intolerance or progression on covalent btki's
-
5:00
comparing btk and bcl-2 inhibitor outcomes in different cll subgroups
-
11:55
updates in cll from eha 2024: combinations of btk and bcl2 inhibitors, btk degraders, and more
-
1:21
improved clinical outcomes in cll when switching from covalent btki to a bcl2i following intolerance
-
1:26
combining btk and bcl-2 inhibitors for the treatment of cll
-
17:23
updates in cll: key clinical trials in the frontline and r/r setting, pre-clinical data and mrd
-
2:39
the safety and efficacy of ibrutinib for the treatment of cll
-
1:55
the evolving role of venetoclax in cll
-
2:25
outcomes & healthcare utilization cost of patients with cll refractory to btk and bcl-2 inhibitors
-
3:12
btk and bcl2 inhibitor resistance in cll: session highlights
-
1:24
sequencing of btk inhibitors in cll
-
4:10
treating cll after intolerance or progression on btki
-
1:48
the importance of evaluating qualitative outcomes of patients with cll on targeted therapy
-
1:14
novel inducers of apoptosis in double-refractory cll cells
-
1:53
clinical outcomes of btki ven treatment in cll/sll: double-exposed vs double-refractory patients
-
2:02
outcomes of patients with cll infected by covid-19 between 2020 and 2022
-
4:44
customizing care in cll with btk inhibitors
-
2:29
the measurement of molecular biomarkers to aid cll treatment
-
1:48
characterizing the development of mds in patients with cll in the era of targeted therapies
-
1:10
the role of next-generation btk inhibitors in the treatment of cll
-
1:11
telomere dysfunction to predict clinical outcomes in cll